STAT

Ebola experts from CDC were pulled from outbreak zone amid security concern

The CDC was forced to withdraw its Ebola experts from an outbreak zone in the Democratic Republic of the Congo several weeks ago amid heightened security concerns.
A nurses working with the World Health Organization prepared to administer Ebola vaccines in the DRC town of Mbandaka in May.

The Centers for Disease Control and Prevention was forced to withdraw its Ebola experts from an outbreak zone in the Democratic Republic of the Congo several weeks ago amid heightened security concerns, a decision that is fueling worry over the impact on efforts to contain the epidemic, according to U.S. officials and public health experts familiar with the matter.

The Ebola experts — among the most experienced on the planet — and other U.S. government employees have been told by the State Department that they cannot travel to eastern DRC to help with the on-the-ground response.

As a result, Dr. Pierre Rollin — a fixture of Ebola responses for decades — has been consigned to the capital, Kinshasa, more than 1,000 miles away, where he is advising the ministry of health. Other CDC staffers are helping DRC’s eastern

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About BIO’s China Challenge, Zepbound Shortages, And More
BIO's about-face in its relationship with WuXi AppTec illustrates the difficulty the biotech industry faces in dealing with an issue that is moving fast and forcefully.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Drug Shortages, Medicare Spending On An Alzheimer’s Drug, And More
Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s manufacturer project.

Related Books & Audiobooks